SCHEMBL5111818

SCHEMBL5111818

CCOC(=O)c1cc(OC(C)C)n[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 2/20 0.50
MAPT P10636 6/20 0.49
RAB9A P51151 4/20 0.49
NPC1 O15118 3/20 0.49
KMT2A Q03164 3/20 0.49
HPGDS O60760 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
TP53 P04637 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
CYP1A2 P05177 1/20 0.42
KDM5A P29375 1/20 0.42
MAPK1 P28482 2/20 0.41
PDE4D Q08499 1/20 0.41
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 2/20 0.41
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27256360 0.83 RAB9A (0.59) ALPLMAPTRAB9ANPC1KMT2A
SCHEMBL3261535 0.83 ALPL (0.54) ALPLMAPTRAB9ANPC1KMT2A
SCHEMBL3216117 0.83 MAPK1 (0.62) ALPLMAPTRAB9ANPC1HPGDS
SCHEMBL1007015 0.79 MAPK1 (0.61) ALPLMAPTRAB9ANPC1KMT2A
SCHEMBL17672388 0.79 HCAR3 (0.47) ALPLTP53KDM5AMAPK1ALDH1A1
SCHEMBL27258675 0.78 ALPL (0.47) ALPLMAPTRAB9ANPC1KMT2A
SCHEMBL2029572 0.78 ALPL (0.52) ALPLMAPTRAB9ANPC1KMT2A
Ethane SCHEMBL6614658 0.78 MAPK1 (0.59) ALPLMAPTRAB9ANPC1KMT2A
SCHEMBL970232 0.77 ALPL (0.57) ALPLMAPTRAB9ANPC1KMT2A
SCHEMBL23844257 0.77 ALPL (0.51) ALPLMAPTRAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026101971-A2 EGFR INHIBITORS FOR TREATING DISEASE BLOSSOMHILL THERAPEUTICS, INC. (US) 2026-05-15 WO disclosed
US-20250353864-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS INC (US) 2025-11-20 US disclosed
WO-2025122859-A1 INDAZOLE-BASED MACROCYCLIC COMPOUNDS BLOSSOMHILL THERAPEUTICS, INC. (US) 2025-06-12 WO disclosed
EP-4536224-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE Blossomhill Therapeutics, Inc. (US) 2025-04-16 EP disclosed
CN-119421709-A Indazole-containing macrocyclic compounds and uses thereof 荣山医药股份有限公司 2025-02-11 CN disclosed
WO-2023240138-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
WO-2023240138-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
US-20080051418-A1 Arylalkanoic Acid Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-02-28 US disclosed
EP-1829863-A1 ARYLALKANOIC ACID DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2007-09-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353864-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE AADAC, PAICS, CYP3A43 ALPL 3735/4885MAPT 1517/4885RAB9A 2308/4885
US-20080051418-A1 Arylalkanoic Acid Derivative INSR, NPY1R, GPR119 ALPL 4260/4885MAPT 4642/4885RAB9A 3734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.